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increasing, and modern series have demonstrated improv-
ing short-term and long-term technical success.3-6 There
is still controversy about the indications for intervention,
the timing of intervention, and whether open or translu-
minal therapy is the appropriate choice. The long-term
functional benefits of endoluminal therapy are not known.
Herein, we report our experience with a consecutive series
of radiologic interventions for atherosclerotic renal artery
stenosis in one well-defined patient population.
METHODS
Experimental design/setting. We performed a retro-
spective analysis of records from patients who underwent
renal artery angioplasty on the basis of intention-to-treat at
the Seattle Division of the Veterans Affairs Puget Sound
Health Care Center between January 1990 and June 1999
in accordance with the policies of the human subjects com-
mittee of the University of Washington. Patients demon-
strating angiographic criteria of fibromuscular dysplasia
were excluded. For each patient, we identified demograph-
ics, existing comorbid conditions (cerebrovascular, cardiac,
renal, and pulmonary), and risk factors for atherosclerosis
(smoking, diabetes mellitus, and dyslipidemia).
Treatment algorithm. All patients with hyperten-
sion, elevated creatinine levels, or diminishing renal mass
Atherosclerotic renal artery stenosis is frequently the
etiology of poorly controlled hypertension, deterioration
of renal function, and recurrent pulmonary edema. The
natural history of this disease is progression; stenoses pro-
ceed to occlusion in about 15% of cases, and deterioration
of renal function will occur in 10% to 20% of cases.1 As a
result, there has been increased emphasis on early evalua-
tion and intervention with the belief that this will result
primarily in ipsilateral renal preservation and secondarily in
the protection of other end organs.2 The incidence of
endoluminal interventions for renal artery disease is
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Purpose: The safety and efficacy of percutaneous transluminal intervention for renal artery stenosis is improving. This
study evaluates the immediate and long-term anatomic and functional outcomes of percutaneous transluminal angio-
plasty and stenting for atherosclerotic renal artery stenosis in a Veterans Affairs population.
Methods: We performed a retrospective analysis of records from patients who underwent renal artery angioplasty with
or without stenting at the Veterans Affairs Puget Sound Health Care System between January 1990 and June 1999.
Indications for intervention included hypertension (78%) and rising serum creatinine (78%). Seventy-six patients (74
men, average age of 67 years, range 42-83 years) underwent 88 attempted interventions. Seventy-two percent of con-
tralateral kidneys had significant disease (47% had a >60% stenosis; 16% were nonfunctioning or absent).
Results: Of the 88 planned interventions, 86 were successfully performed with placement of 46 stents (52%). Technical
success (defined by <30% residual stenosis) was achieved in 78 vessels (89%). The procedure-related complication rate
was 5%. Patient mortality by life table analysis was 49% at 5 years. Assisted primary patency rate at 5 years was 100%.
Primary and secondary restenosis rates were 37% ± 8% and 31% ± 8% at 5 years, respectively. Sixty-eight percent of
patients treated for hypertension demonstrated clinical benefit (improved or cured hypertension). This clinical benefit
was maintained in 52% of the patients at 5 years, as measured by life table analysis. Serum creatinine was lowered or
maintained in 88% of the patients, but this clinical benefit was only maintained in 25% of patients at 5 years.
Conclusions: Transluminal intervention for clinically symptomatic atherosclerotic renal artery stenosis is technically suc-
cessful and safe. There are excellent assisted-patency and low restenosis rates. There is immediate clinical benefit for
most patients, as evidenced by improved control of hypertension and preservation of renal function. However, within
5 years the benefit is not maintained for either hypertension (50%) or renal function (20%). Therefore, although tech-
nically successful, functional outcomes after endoluminal intervention are not maintained in the long term. (J Vasc
Surg 2001;34:685-93.)
underwent duplex ultrasound scanning (Table I). In the
presence of clinical symptoms and ≥60% renal artery
stenosis, angiography was performed, with interventions
performed for renal artery stenoses ≥50%. We did not treat
nonfunctioning kidneys and kidneys with a pole-to-pole
length on ultrasound of <9 cm. In the presence of bilateral
disease, the clinical criteria for treatment of the contralat-
eral side were the same as those for the primary side (ie,
we would always treat bilateral disease). Patients were fol-
lowed with serial duplex scans for 6 months after the pro-
cedure and then at yearly intervals thereafter. During
follow-up, patients with recurrent ≥60% stenosis on
duplex were followed every 6 months unless they devel-
oped recurrent symptoms (ie, hypertension or further ele-
vation in creatinine), in which case the lesions were
immediately imaged by angiography and treated if ≥50%
restenosis was documented.
Definitions. Hypertension was defined as a systolic
blood pressure greater than 150 mm Hg or diastolic blood
pressure greater than 90 mm Hg on three occasions dur-
ing a 6-month period. An elevated creatinine level was
considered if two consecutive values during a 3-month
period were greater than 1.5 mg/dL, and declining renal
function was defined as >20% increase in serum creatinine
during a 6-month period. The baseline serum creatinine
level was the level recorded closest to the date on which
the patient underwent angioplasty. A combined category
of hypertension and rising creatinine level was also
included, because this was a common occurrence. Patients
were considered to have a “nonfunctioning kidney” if any
two of the following criteria were met: (1) a duplex ultra-
sound scan identified a pole-to-pole length of less than 
9 cm with no renal flow in main renal artery and parenchy-
mal peak systolic velocity <10 cm/s; (2) surgically or con-
genitally absent kidney; (3) no visible nephrogram on
contrast arteriogram. Ostial lesions were defined as lesions
within 1 cm of the orifice. A procedural success was
defined by a residual stenosis of <30%; failures were
defined as residual stenoses ≥30%, by angiographic mea-
surement, including lesions unable to be dilated or
crossed. A death within 30 days of procedure was consid-
ered procedure-related. Assisted primary patency was
defined as the absence of occlusion of the vessel after the
primary intervention but including any interventions to
treat restenosis. Restenosis was defined as a treated seg-
ment with a duplex classification of ≥60% stenosis.
Secondary restenosis was defined as a treated segment
with a duplex classification of ≥60% stenosis after addi-
tional percutaneous interventions. Response in the hyper-
tensive patient was defined by previously published
criteria8 as follows: “cured” patients were normotensive
(diastolic blood pressure <90 mm Hg) without medica-
tions; improved patients were normotensive with therapy,
had a diastolic blood pressure 15% below baseline, or had
elimination of two or more antihypertensive medications).
Late outcome with respect to hypertension was defined as
recurrence of diastolic blood pressure >90 mmHg or a
>20% increase of postprocedure baseline diastolic blood
pressure that was not treatable by repeat angioplasty. The
following definitions of early and late renal function
response to angioplasty were used: “improvement” in
renal function required a ≥20% reduction in the serum
creatinine concentration; renal function was considered to
have “deteriorated” if there was a >20% increase in the
serum creatinine concentration.9 Patients who had ≤20%
change in serum creatinine after the procedure were con-
sidered to have “stable” renal function. Late outcomes for
renal function response were classified as “continued dete-
rioration” if patients went onto dialysis, died of renal-
related causes during follow-up, or had a late serum
creatinine level >20% of postprocedure concentrations.
Statistical analysis. Measured values are reported as
percentages or means ± 1 standard deviation. Standard
errors are reported in life table analyses. Cumulative
assisted patency, restenosis, and clinical benefit rates are
calculated by using the life table method and reported
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Table I. Renal duplex criteria for renal artery stenosis
Category Renal artery PSV (cm/s) Renal to aortic ratio
Normal <180 <3.5
<60% >180 >3.5
≥60% >180 ≥3.5
Occluded No flow NA
PSV, Peak systolic velocity; NA, not applicable.
Table II. Patient characteristics
Characteristic n (%)
Cardiac
Hypertension 74 (97)
Myocardial infarction 52 (68)
Congestive heart failure 42 (55)
Stable angina 18 (24)
Cerebrovascular
Transient ischemic attack or confirmed 31 (41)
stroke
Renal
Normal creatine level (<1.5) 27 (35)
Elevated creatinine level (>1.5) 49 (65)
Pulmonary
Chronic obstructive pulmonary disease 28 (37)
Risk factors
Smoking 64 (84)
Dyslipidemia 59 (78)
Diabetes mellitus 22 (29)
Insulin-dependent 13 (17)
Non–insulin-dependent 9 (12)
Previous cardiovascular surgery
Carotid endarterectomy 9 (12)
Aortic reconstruction 13 (17)
Lower extremity revascularization 9 (12)
Coronary artery bypass 14 (18)
using the North American chapter of the International
Society for Cardiovascular Surgery/Society for Vascular
Surgery criteria. Cox proportional hazards model was
employed to determine the influence of preprocedural and
periprocedural factors on outcomes (survival, restenosis,
clinical benefit). Differences between groups of categori-
cal data were tested for significance with the Mann-
Whitney rank sum test or χ2 analysis. Statistical
significance was assumed for P < .05.
RESULTS
Patient population. Seventy-six patients were identi-
fied (74 men, 2 women; mean age, 67 years; range, 42-83
years). Comorbidities, general risk factors, and previous
cardiovascular surgery were typical for a population with
symptomatic peripheral vascular disease (Table II).
Indications and procedures. Eighty-eight stenotic
renal arteries present in 76 patients required intervention.
Indications for intervention included hypertension in 49%,
elevated creatinine levels in 19%, and both hypertension
and elevated creatinine levels in 29% (Table III). There
was significant disease in the contralateral kidney in 72% of
the patients (≥60% duplex renal artery stenosis, 47%; non-
functioning kidney, 16%; angiographic evidence of renal
artery occlusion, 6%; previous nephrectomy, 3%). The
anatomic location of the stenosis was ostial in 36% (Table
III). Stents were placed in 51% of the cases. Seventeen of
forty-one (41%) contralateral renal arteries with angio-
graphically-confirmed stenotic disease were treated when
and where possible to obtain maximal therapeutic benefit.
In the remainder of the population, we did not intervene
because the kidney was small (<9 cm pole-to-pole length),
the patient died before we were able to address the con-
tralateral side, or the patient refused additional therapy.
Immediate outcomes (<3 months). In 2 vessels
(2%), the lesion could not be crossed, and these were
deemed immediate intention-to-treat failures. Technical
success was achieved in 78 vessels (89%). Six procedure-
related complications occurred in four interventions (5%).
These included 3 groin hematomas, 1 retroperitoneal
bleed, and 2 femoral artery pseudoaneurysms. No deaths
occurred from renal artery injury. Three patients died
within 30 days of the procedure for a 1-month mortality
of 3.8%.
In the 25 patients who had immediate preprocedure
and postprocedure duplex scans, renal artery velocities
decreased, indicating reduction of stenosis. Peak systolic
velocity decreased from 392 cm/s to 132 cm/s (P <
.0001), and the renal-to-aortic peak velocity ratio decreased
from 4.9 to 2.3 (P < .0001). There was good agreement
between the postoperative duplex and the angiographic
final result (χ2 56.36, 9 df, P < .001).
Sixty-eight percent of the patients treated for hyper-
tension showed immediate clinical improvement (Table
IV), which was accompanied by no change or a decrease
of one or more antihypertensive medications in 75% of
patients (no change in 45%, decrease in 30%) (Table V). In
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patients treated for elevated creatinine concentrations
(>1.5g/dL), 86% showed maintenance of or a decrease in
serum creatinine levels after the procedure. The mean
absolute creatinine levels did not change significantly in
any group (Table V).
Outcomes (>3 months). Average follow-up was 1.5
years (range, 0 to 7.9 years for 79 of 88 interventions).
Patient mortality was 49% at 5 years, with a significant dif-
ference in mortality between the patients treated for
hypertension and the patients treated for elevated creati-
nine levels (Fig 1). There was a significant association
between the response of the hypertensive patient with a
normal creatinine level to angioplasty and survival (χ2
6.39; 2 df, P = .04). Interventions for elevated creatinine
levels did not significantly affect the patients’ long-term
outcomes.
Assisted primary patency was 100% at 5 years (no ves-
sels occluded). Primary and secondary restenosis rates at 5
years were 37% ± 8% and 31% ± 8%, respectively (Fig 2).
Restenosis was significantly lower for the group with an
initial technically successful procedure (22% ± 8% at 5
years; P < .05). There was a trend toward decreased
restenosis for vessels treated with a stent.
There was a change in duplex category (0 to <60%,
<60% to ≥60%) in the treated vessels with time. The
cumulative incidence was 6% ± 2% at 1 year, 23% ± 3% at
2 years, and 37% ± 11% at 4 years for all categories. In the
14 vessels with >60% restenosis by duplex, six (7%, all
proximal lesions) underwent repeat angioplasty with no
sequelae. The indications to reintervene were renal dys-
function in four patients and recurrent hypertension in
two patients. After the second angioplasty in the 6
patients with recurrent symptoms, their parameters
returned to baseline. In the 8 patients whose clinical
symptoms were treated, none of these vessels occluded
during follow-up. The initial indications for therapy in
Table III. Indications and procedural data
n (%)
Indications of stenosis
Hypertension 43 (49)
Hypertension with rising creatinine level 25 (29)
Rising creatinine level 17 (19)
Shrinking kidney mass 1 (1)
Pulmonary edema 1 (1)
Unknown 1 (1)
Preprocedure anatomy
Side (right) 44 (50)
Site of stenosis
Ostial 32 (36)
Proximal 52 (59)
Middle 3 (3)
Distal 1 (1)
Procedure
Angioplasty 86 (98)
Stent placement 46 (52)
Treatment failure 2 (2)
these 14 vessels were hypertension,11 elevated creatinine
levels,2 and combined hypertension and elevated creati-
nine levels.1 After the initial angioplasty in the hyperten-
sive group, the functional results at 3 months were cured
(1), improved (7), and unchanged (3). Both patients
treated for renal dysfunction were classified as improved
at 3 months. The single patient with both hypertension
and an elevated creatinine level showed improvement in
the hypertension component whereas the renal dysfunc-
tion component was unchanged.
Cumulative freedom from dialysis, renal disease–related
mortality, and >20% elevation in postprocedure creatinine
levels was 89% ± 5%, 44% ± 9%, and 25% ± 10% at 1, 3, and
5 years, respectively (Fig 3). Five patients ultimately required
dialysis within 3 years of their interventions (preprocedure
creatinine levels were 3.5, 4.0, 4.0, 4.1 and 4.8 mg/dL). All
five patients showed worsening renal function after the renal
angioplasty. Of these, 2 had a nonfunctioning contralateral
kidney, 1 had a >60% stenosis with a small kidney (<9 cm
pole-to-pole length), and 2 were considered to have normal
contralateral renal arterial anatomy. There were no signifi-
cant factors in the preprocedure history that were associated
with the future need for dialysis. Cumulative freedom from
recurrent hypertension (>90 mm Hg or >20% increase in
postprocedure diastolic blood pressure where that pressure
was never <90 mm Hg) was 87% ± 6%, 71% ± 9% and 52%
± 10% at 1, 3, and 5 years, respectively (Fig 4).
By using Cox proportional hazards model, we found
significant correlations between the presence of ischemic
heart disease in the preprocedural history, chronic renal
insufficiency and diastolic blood pressure, and ultimate
mortality (Table VI). Insulin-dependent diabetes mellitus,
chronic renal insufficiency, and systolic blood pressure
were associated with development of restenosis (Table
VI).
DISCUSSION
Mortality. Untreated renal artery stenosis is a signifi-
cant independent predictor of mortality. Seventy-three
percent of patients with renal artery stenosis are dead at 7
years.1,10 The cumulative mortality rate after therapy in
this study (49% at 5 years) appears to be the same as that
from untreated renal artery stenosis. The presence of
ischemic heart disease, chronic renal insufficiency, and ele-
vated diastolic blood pressure correlated with ultimate
mortality. This is consistent with the literature, in that
each is an independent risk factor for atherosclerosis and
atherosclerosis-related mortality, and with studies showing
that survival after renal artery angioplasty with and with-
out stenting is adversely affected by baseline renal func-
tion. The presence of clinical benefit after angioplasty at 3
months in the hypertensive group, but not in the group
with elevated creatinine levels, did impact mortality at 5
years. Surgical revascularization is associated with an initial
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Table IV. Intermediate clinical response
Response*
Indication n Worse No change Improved Cured
Hypertension 69 0% 29% 53% 18%
Elevated creatinine level 41 14% 76% 10% NA
*Values are percentages of total treated patients for the respective subgroup.
Table V. Intermediate outcomes
Indication Parameter n Preprocedure* Postprocedure* P value
All
SBP (mm Hg) 59 173 ± 4 144 ± 3 < .001
DBP (mm Hg) 58 91 ± 3 79 ± 2 < .001
No. medications 51 2.7 ± 0.2 2.1 ± 0.1 < .001
Creatinine level (mg/dL) 60 2 ± 0.1 2 ± 0.2 .9
Hypertension
SBP (mm Hg) 48 178 ± 5 144 ± 3 < .001
DBP (mm Hg) 47 94 ± 3 80 ± 2 < .001
No. medications 44 2.7 ± 0.2 2.1 ± 0.2 < .001
Creatinine level (mg/dL) 47 1.9 ± 0.1 1.8 ± 0.1 .5
Elevated creatinine level
SBP (mm Hg) 26 158 ± 5 141 ± 4 .002
DBP (mm Hg) 26 86 ± 4 75 ± 2 .01
No. medications 21 2.9 ± 0.2 2.2 ± 0.2 .03
Creatinine level (mg/dL) 27 2.4 ± 0.2 2.5 ± 0.3 .7
*Values are the mean ± standard error of the mean.
SBP, Systolic blood pressure; DBP, diastolic blood pressure.
mortality related to the operative procedure, which is
approximately 2% to 5%. Hallet11 reported a 5-year mor-
tality rate of 34%, whereas Steinbach12 reported 5-year
and 10-year mortality rates of 19% and 47%, respectively.
These data are superior to those quoted for renal angio-
plasty with or without stent placement. Factors associated
with late death after surgical revascularization were pre-
senting age >60 years, presence of ischemic heart disease
or diabetes, and preoperative congestive heart failure.9,12
The presence of a creatinine level >2 mg/dL was also asso-
ciated with a deterioration in renal function and a proba-
bility of death of 48% at 5 years.
In the current study, the 30-day morbidity (5%) and
mortality (4%) rates compare favorably with results of
other studies of endoluminal intervention for renal artery
stenosis3-5,13,14 and are comparable with surgical
series.9,12,15,16 We found similar factors affecting mortality
(ie, coronary artery disease and renal dysfunction).
Surgical and angiographic patient populations are not
likely to be comparable because patients who are deemed
poor surgical risks are not referred for surgical evaluation.
In a retrospective review comparing a single institution’s
therapy for ischemic nephropathy where both surgery and
endoluminal therapies were used and where the patient
groups were similar, Mills17 found that surgical recon-
struction produced more durable patency and functional
improvements as compared with endoluminal therapy.
The immediate failure rate of 11% also compares favorably
with previously reported rates of 10% to 20% for angio-
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plasty with or without stent placement.3,4,14 In a prospec-
tive randomized study, Weibull18 reported that as much as
17% of the patients treated with renal angioplasty required
surgical intervention to maintain therapeutic efficacy. We
did not encounter this high rate of surgical intervention;
we did not have to intervene to salvage any kidneys dur-
ing the 7 years, and even with a conservative reinterven-
tion policy we did not see any occlusions.
Anatomic results and patency. Excluding technical
failures, we had a 100% assisted-patency rate and a favor-
able restenosis rate. These data are consistent with pub-
lished data. Overall success rates of transluminal
angioplasty are 55% for ostial lesions and 70% for all
lesions. Overall success rates of transluminal angioplasty
with placement of a stent are reported in the range of 96%
to 100%. Pooled data suggest a restenosis rate of 15% to
20% for transluminal angioplasty with placement of a stent
and 30% for transluminal angioplasty at 8 months. Reports
on surgical revascularization have shown excellent short-
term and long-term patencies that are comparable to renal
angioplasty.12,19
The natural history of untreated renal artery stenosis is
progression with an average rate of 7% per year. Patients in
the >60% category have a rate that is higher, at 13% per
year. Cox proportional hazards model identified four base-
line factors associated with renal artery disease progres-
sion—presence of high-grade stenosis or occlusion of the
contralateral renal artery, age, elevated systolic blood pres-
sure, and diabetes. In the present study, we found that
Fig 1. Life table analysis of the entire study population (circles) and of those patients treated for hyper-
tension (triangles) or elevation in creatinine level (squares). The number of patients in each interval is
given in the table.
insulin-dependent diabetes, chronic renal insufficiency,
and elevated systolic blood pressure were associated with
the development of >60% restenosis. For untreated arter-
ies classified as normal or having <60% stenosis at the
beginning of a prospective study on renal artery stenosis
using duplex criteria by Zierler,10 there was a 3-year
cumulative incidence of progression to the >60% stenosis
of 13% and 56%, respectively. This study demonstrates an
average rate of yearly progression from normal to <60%
stenosis using similar duplex criteria of 9% per year or 34%
at 3 years. Progression to restenosis or >60% duplex steno-
sis was 30% at 3 years. We observed a conservative
approach to restenosis. We assessed restenosis using the
same criteria as for the original lesion (ie, whether it was
causing symptoms that required treatment). Although we
tracked our patients with duplex scanning and encoun-
tered 14 lesions that were >60% on duplex criteria, only six
had recurrent symptoms, which were ameliorated by a sec-
ond endoluminal intervention. It could be argued that the
initial lesion was not the cause of the initial symptoms;
however, we have clearly shown that each of the patients
demonstrated an appropriate response to the initial ther-
apy, suggesting that such an argument is invalid.
Functional outcome. Given the fact that we have
demonstrated no change in the mortality for these
patients, it is important to have produced a beneficial
functional/physiologic outcome in either hypertension or
renal function, which was the intent of therapy. In patients
with hypertension, a significant decrease in blood pressure
was achieved. From the pooled data extracted from 20
reports on transluminal angioplasty, it appears that hyper-
tension is cured in 13% and improved in another 67% of
all cases.20 Data from 13 reports of transluminal angio-
plasty with stent placement covering as many as 2 years
follow-up, it appears that hypertension is cured in 8% and
improved in 56% of cases.20 In the present study, mainte-
nance of clinical benefit from hypertension by life table
analysis was only 52% at 5 years, but this did impact on
predicted patient survival. Steinbach12 reported long-term
cure and improvement of renovascular hypertension in
72%, with a mean follow-up of 7.4 years. Cost-effective-
ness analyses have suggested that renal angioplasty is cost
effective as long as there is a significant decrease in the
patient’s medical requirements (eg, reduction of hyper-
tensive medications by 3 drugs).19,21 We did not achieve
this level of reduction. Thus, based on this benchmark, we
failed the cost-effectiveness assessment. However, in par-
tial mitigation of this lack of reduction in antihypertensive
medications, we did include diuretics, angiotensin-con-
verting enzyme inhibitors, calcium channel antagonists, β
blockers, and nitrates in our medication counts. Given the
facts that the level of comorbid conditions is high in this
study and many drugs have dual actions, the modest
decrease should not be surprising. A recent study examin-
ing renal artery angioplasty versus best medical therapy for
hypertension suggested that transluminal angioplasty may
not convey a significant prolonged functional improve-
ment.22 There was significant crossover in the study. Sixty-
nine percent of these patients were considered to have
improved blood pressure control, and 9% were considered
to have worsened blood pressure control, but only 45%
were considered to be cured. This pattern of response is
very similar to the data obtained in this study. The authors
did note that the number of medications prescribed to the
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Fig 2. Cumulative primary (circles) and secondary (squares) stenosis-free intervals for all vessels. The
number of vessels at each interval is given in the table. Values are the mean ± standard errors <10% for all
data points.
transluminal angioplasty group was decreased at 3 months
but similar to the untreated cohort at 12 months.22
In patients with chronic renal insufficiency, pooled
data from 12 reports on transluminal angioplasty with
placement of a stent suggests a 35% improvement rate and
a 35% stabilization rate for the first 2 years.20 Steinbach12
reported that long-term improvement or stabilization of
renal function was achieved in 71% of patients after surgi-
cal revascularization. Hansen et al16 have seen similar
trends and have also identified patients with acutely dete-
riorating renal function as those with the most favorable
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outcome. Creatinine concentrations were unchanged by
our interventions, and this plateau was maintained for 2
years; thereafter, a rising trend was evident. This correlates
with the need in five patients for renal dialysis within 3
years. By life table analysis, we had a very poor predicted
maintenance of clinical benefit—25% of patients at 5 years.
It can be argued that on an “intention-to-treat basis,” this,
too, represents a poor outcome. Most series of renal
angioplasty or surgical interventions demonstrate a stabi-
lization of creatinine concentrations and a low number of
patients progressing to dialysis.3,4,9,12,14,16 Many series
Fig 3. Life table analysis of likelihood of continued deterioration in renal function after renal angioplasty.
Data are the mean ± standard error. The number of patients in each interval is given in the table.
Fig 4. Life table analysis of likelihood of continued deterioration in blood pressure after renal angioplasty.
Data are the mean ± standard error. The number of patients in each interval is given in the table.
report improvement in 48% to 83% of patients treated,
with preservation of renal function as the primary indica-
tion. Our results are mixed, in that we did achieve imme-
diate stabilization of creatinine concentrations in 88% of
the patients but this clinical benefit was not sustainable for
5 years. This occurred despite therapy for any contralateral
disease and selecting patients with >9 cm pole-to-pole kid-
ney lengths. It likely reflects a late referral pattern, a poor
case mix, a selection problem, or an overly aggressive
intervention policy, such that irreversible end-organ dam-
age had already occurred and the organs could not be sal-
vaged.
Conclusions. This study shows that transluminal
intervention for clinically symptomatic atherosclerotic
renal artery stenosis is technically successful and safe.
There are excellent assisted patency and low restenosis
rates. Duplex surveillance reveals evidence of gradual pro-
gression to <60% stenosis. There is immediate clinical ben-
efit for most patients, as evidenced by improved control of
hypertension and preservation of renal function. In the
hypertensive patient, there was a survival advantage.
However, within 5 years, this benefit was not maintained
for either hypertension (50%) or renal function (20%).
Therefore, although technically successful, functional out-
comes after endoluminal intervention are not maintained
in the long term.
We appreciate the vascular technologists (Kim
Cantwell-Gab, RN, RVT, Sandra Steiner, RVT, Linda
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all of the follow-up duplex scans, and Deborah Deese,
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